CM: Cardiomyopathie; PN: Polyneuropathie.

Références:

1. Nativi-Nicolau, J.N., et al., Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev, 2022. 27(3): p. 785–793. 
2. Gertz, M.A., Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care, 2017. 23(7 Suppl): p. S107–S112. 
3. Adams, D., et al., Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis, 2021. 16(1): p. 411. 
4. Gertz, M., et al., Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract, 2020. 21(1): p. 198.